Alopecia Universalis in a Multiple Sclerosis Patient After Switching From Rituximab to Ocrelizumab: A Case Report

This case report describes a 37-year-old woman with secondary progressive multiple sclerosis (SPMS) who developed alopecia universalis after switching her treatment from rituximab to ocrelizumab. Ocrelizumab, a humanized monoclonal antibody used for treating multiple sclerosis, may trigger autoimmune reactions such as alopecia universalis in immunocompromised patients. The patient experienced rapid progression from patchy scalp hair loss to total body hair loss within 3-4 days after receiving her second dose of ocrelizumab. This is the first reported case of such an occurrence, highlighting a potential side effect of ocrelizumab in similar patients.